Want to see GB:SCLP full AI Analyst Report?
SCLP Stock Chart & Stats
9.62 p
0.24 p(2.55%)
At close: 4:00 PM EDT
9.62 p
0.24 p(2.55%)
Day’s Range― - ―
52-Week Range89.50 p - 295.00 p
Previous CloseN/A
Volume20.19M
Average Volume (3M)1.91M
Market Cap
£109.34M
Enterprise Value157.05M
Total Cash (Recent Filing)£5.32M
Total Debt (Recent Filing)£17.08M
Price to Earnings (P/E)―
Beta-0.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,212,230,700
10 Day Avg. Volume1,265,515
30 Day Avg. Volume1,907,035
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)-7.48
Price to Sales (P/S)0.00
P/FCF Ratio-13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ReadinessFDA clearance materially reduces a key development barrier by validating the proposed clinical and manufacturing package for Phase III. Acceptance of a surrogate endpoint also creates a potential accelerated-approval route, strengthening the program’s regulatory and commercial pathway over the next several years.
Clinical Efficacy SignalThe Phase II signal provides meaningful evidence that iSCIB1+ may improve outcomes when added to standard immunotherapy, supporting progression into a registrational trial. Although confirmation is required, the result can improve partnering appeal and reinforce the lead program’s strategic importance.
Pipeline And Platform DepthMultiple internal and partnered programs diversify the company beyond a single clinical asset and create several routes to future value. Genmab collaboration, potential milestones, royalties, patented technologies and scalable manufacturing could support non-dilutive funding and broader platform validation.
Bears Say
Persistent Operating LossesThe absence of revenue and persistent operating losses show that the business has not yet established commercial earnings power. Negative gross profit in 2026 also highlights weak operating leverage, leaving future progress dependent on clinical success, partnerships or external capital.
Cash Burn And Weak Balance SheetSustained cash outflows combined with negative equity and a shrinking asset base materially reduce financial flexibility. Debt remains substantial relative to the balance sheet, so funding Phase III and ongoing research may require financing or milestone receipts that could constrain strategic choices.
Funding And Clinical Timing RiskThe long interval before definitive Phase III data leaves the company exposed to several years of execution and financing needs without regular efficacy updates. With runway ending well before the target readout, additional funding, partnering or milestone receipts appear necessary to sustain development.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 89.50 p and its highest was 295.00 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £109.34M.
When is Scancell Holdings PLC’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scancell Holdings PLC’s earnings last quarter?
Currently, no data Available
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,212,230,700 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.54%
12-Months-Change
Fundamentals
Return on Equity
128.87%
Trailing 12-Months
Asset Growth
-55.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Scancell Holdings PLC
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―